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The role of fibroblast growth factor (FGF) in orbital fibroblasts (OFs) is rarely known. In this
study, we investigated the effect of FGF10 on fibrosis and the inflammation mechanism of
Graves0 orbitopathy (GO).
Methods
Orbital tissue from GO (n = 15) and non-GO (n = 15) was obtained for this study. The mRNA
and protein expression levels of FGF10 and FGF receptor 2b (FGFR2b) in orbital tissue
were determined by real-time polymerase chain reaction, western blot analysis, and confo-
cal microscopy. The effects of FGF10 on transforming growth factor (TGF)-β1 induced
fibrotic proteins and interleukin (IL)-1β- or tumor necrosis factor (TNF)-α- induced inflamma-
tory proteins were investigated using recombinant human (rh) FGF10 and small interfering
(si) RNA transfection against FGF10.
Results
FGF10 and FGFR2b mRNA expression levels were significantly lower in GO orbital tissues
than in non-GO orbital tissues (p = 0.009 and 0.005, respectively). Immunostaining of
FGF10 in orbital adipose tissues showed differences in FGF10 expression between GO and
control samples. Immunostaining of FGF10 was very weak in the orbital tissues of GO
patients. TGF-β1-induced fibronectin, collagen Iα, α-smooth muscle actin protein expres-
sion in GO OFs was attenuated by rhFGF10 treatment and increased by knockdown of
FGF10 via siFGF10 transfection. Similarly, IL-1β- or TNF-α-induced IL-6, IL-8, and cycloox-
ygenase-2 protein production in GO OFs was either blocked by rhFGF10 treatment or fur-
ther upregulated by inhibition of FGF10 via siFGF10 transfection.
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Conclusions
Our data demonstrate that FGF10 has beneficial effects on the inflammatory and fibrotic
mechanisms of GO in primary cultured OFs, providing new insights into GO pathology and
the discovery of FGF10 as a promising novel therapeutic application for the treatment of
GO.
Introduction
Graves0 orbitopathy (GO) is an inflammatory autoimmune disease of the extraocular muscles
and orbital fat or connective tissue, generally observed in patients with Graves’ disease [1].
Although the pathogenesis of GO remains unclear, orbital fibroblasts (OFs) play a key role in
the disease process. OFs express the thyroid-stimulating hormone receptor (TSHR) and activa-
tion of the OFs by inflammatory mediators and stimulatory autoantibodies directed against
the TSHR and insulin-like growth factor-1 receptor enhance inflammation, hyaluronic acid
production, adipogenesis, and fibrosis in GO patients [2, 3]. Fibrosis can be followed by
inflammation as a part of the wound healing process [4, 5]. Although the clinical course of GO
is variable, usually an initial active inflammatory phase, lasting 6 to 24 months, is followed by a
chronic fibrosis phase [6].
Fibroblast growth factor (FGF) was discovered as a mitogen for cultured fibroblasts [7].
FGFs play important roles during embryonic development and adult organisms by regulating
cell proliferation, differentiation, migration, survival, angiogenesis, and organogenesis [8, 9].
Over the last few years, 22 distinct FGFs have been identified. Although the roles of FGFs in
OFs are rarely known, basic FGF (FGF2) has been proposed to contribute to GO [2, 10, 11].
Previous reports demonstrated that serum and tissue FGF2 levels were increased in patients
with active GO, suggesting that FGF2 could reflect the ocular inflammatory activity in GO
patients. However, besides FGF2, the role of FGFs in OFs has rarely been studied. Based on
phylogenetic analysis, FGF family is further divided into seven subfamilies: FGF1 and FGF2
(FGF1 subfamily); FGF4, FGF5 and FGF6 (FGF4 subfamily); FGF3, FGF7, FGF10 and FGF22
(FGF7 subfamily); FGF11, FGF12, FGF13 and FGF14 (FGF11 subfamily); FGF19, FGF21, and
FGF23 (FGF19 subfamily) [12]. FGF7, also known as a keratinocyte growth factor-1 (KGF1)
and FGF10 (KGF2), interacts with one of the FGF receptors (FGFRs), expressed particularly
by epithelial cells, and may serve as a protective factor for epithelial tissue.
FGF10, belonging to the FGF7 subfamily, activates key intracellular signaling pathways in
several cell types, leading to the modulation of cell proliferation, differentiation, and migration
during wound healing and tissue repair [13]. Gupte et al. [14] reported that overexpression of
FGF10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmo-
nary fibrosis in mice. Sun et al. [15] showed that reduced expression of FGF10/FGFR2 was
found in rats with di-n-butyl phthalate-induced renal fibrosis. FGF10 has been detected in the
cytoplasm of cultured prostate stromal cells [16] and the nucleus of urothelial cells [17], sug-
gesting that different subcellular localization of FGF10 can be possible underlie the specificity
of FGF10 signaling in different cell type. In epithelial cells, upon FGF10 binding, FGFRs
dimerize, and several intracellular tyrosine residues are trans-autophosphorylated. FGFR
engages multiple and complex signaling pathways via adaptor proteins in epithelial cells [18].
As GO is an inflammatory and fibrotic disease, it was hypothesized that FGF10 might par-
ticipate in its pathogenesis. However, to the best of our knowledge, few previous reports
regarding the association between FGF and GO mechanisms. Of the various types of FGFs, we
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focused on FGF10 and aimed to determine whether FGF10 decreased the expression of mole-
cules associated with inflammation and fibrosis in an in vitro model of GO.
Materials and methods
Cultures
Orbital adipose tissues were obtained from GO patients as surgical waste during orbital
decompression for exophthalmos (n = 15; 6 men, 9 women; aged 25–65 years). The decom-
pression surgery was performed in an inactive phase of GO for rehabilitative purposes, and
thyroid hormones were well controlled during surgery. Clinical activity scores at the time of
surgery were less than 3. None of the patients with GO had received steroid or radiotherapy
treatment for at least 6 months prior to the surgery. Non-GO orbital tissue samples were col-
lected during eyelid or orbital surgery from age- and sex-matched non-GO subjects with no
history or clinical evidence of thyroid disease (n = 15; 6 men, 9 women; aged 23–71 years).
Three patients underwent orbital surgery for other non-inflammatory diseases and 12 patients
underwent cosmetic upper and lower blepharoplasty. The study was approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University College of Medicine. Written
informed consent was obtained from all patients who were enrolled in this study. This study
followed the tenets of the 1975 Declaration of Helsinki.
The established methods of the primary culture were used for the primary culture of OFs
[5, 19]. Briefly, the adipose tissue was minced and placed in 1:1 Dulbecco’s modified Eagle’s
medium (DMEM): F12 medium with 20% fetal bovine serum (FBS) and penicillin/gentamy-
cin. Fibroblasts were cultured from the explants, and then monolayers were passaged serially
with trypsin/ethylenediaminetetraacetic acid (EDTA). Cultures were maintained in DMEM:
F12 with 10% FBS and antibiotics. Fibroblasts between the second and fifth passages were used
for analysis.
Reagents
DMEM: F12 and penicillin-streptomycin were purchased from WelGENE Inc. (Daegu,
Korea). FBS was purchased from Invitrogen (Carlsbad, CA, USA). FGF10 antibody, recombi-
nant human (rh) FGF10, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and transform-
ing growth factor (TGF)-β1 were purchased from R&D Systems (Minneapolis, MN, USA).
Small interfering (si) FGF10 was purchased from Horizon Discovery Ltd. (Lafayette, CO,
USA). Negative controls were purchased from Invitrogen. We purchased fibronectin from BD
(Franklin Lakes, NJ, USA) and α-smooth muscle actin (SMA) antibody was purchased from
Sigma-Aldrich (St. Louis, MO, USA). IL-6 antibody was purchased from Novus Biologicals
(Centenial, CO, USA). Collagen Iα (COL1A) and IL-8 antibodies were purchased from
Abcam (Cambridge, UK). Matrix metalloproteinase (MMP)-2, cyclooxygenase (COX)-2,
extracellular signal-regulated kinase (ERK), and phospho-ERK were purchased from Cell Sig-
naling Technology (Danvers, MA, USA). Collagen IIIa (COL3A) and β-actin were purchased
from Santa Cruz Biotechnology (Logan, UT, USA).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Orbital tissue specimens (n = 10 for GO, n = 10 for non-GO) were used to compare the
mRNA levels of FGF10 and FGFR2 using qRT-PCR. In primary cultured OFs from GO and
non-GO cells, mRNA expression levels of fibronectin, COL1A, and α-SMA were measured
using qRT-PCR. Orbital tissues were homogenized with a tissue homogenizer (Precellys1 24;
Bertin Instruments, Montigny-le-Bretonneux, France) using a Precellys lysing kit (Bertin
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Instruments) with Trizol (Invitrogen, Thermo Fisher Scientific, Waltham, MA). RNA was
extracted from the cells using TRIzol (Invitrogen), and the RNA concentration was deter-
mined using NanoDrop (Thermo Fisher Scientific). A total of 1 μg of mRNA was reverse-tran-
scribed into cDNA (SensiFAST cDNA Synthesis Kit; Meridian Life Science, Memphis, TN,
USA) and amplified with SYBR green PCR master mix (TaKaRa Bio, Shiga, Japan) and Taq
Man™ Gene Expression Master Mix (Thermo Fisher Scientific) using the LightCycler1 480
System (Roche, Basel, Switzerland). All PCR reactions were performed in triplicates, and all
samples were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression
levels. The primers used for amplification were as follows: FGF10, 50-GAA GGA GAA CTG
CCC GTA CA-30 (forward) and 50-GGC AAC TCC GAT TTC TAC T-30 (reverse);
FGFR2b 50-GCT GGC TCT GTT CAA GAC-30 (forward) and 50-GGC CTG CCC TAT
ATA ATT GGA-30 (reverse); GAPDH 50- TGC TGT AGC CAA ATT CGT TG-30 (for-
ward) and 50- CAC CCA CTC CAC CTT T-30 (reverse). TaqMan gene expression assay
targets: Hs00426835_g1 for α-SMA, Hs01549976_m1 for fibronectin, Hs00164004_m1 for
COL1A, and Hs99999905_m1 for GAPDH (Thermo Fisher Scientific).
Western blots
Western blot analyses of FGF10, fibronectin, COL3A, COL1A, α-SMA, MMP-2, IL-6, IL-8,
cyclooxygenase (COX)-2, intercellular adhesion molecule (ICAM)-1, total ERK and phospho-
ERK were performed as described previously [19, 20]. The relative densities were quantified
and normalized to that of β-actin in the same sample. Full length gels representative of West-
ern blot analysis were provided in S1–S4 Figs.
ELISA analysis
FGF10 expression was analyzed using a human cytokine ELISA kit (Abbexa Ltd., Cambridge,
UK) according to the manufacturer’s protocol. Levels of FGF10 in GO OFs under IL-1β, TGF-
β, and TNF-α stimulation were determined. ELISA was used to determine levels of secreted
FGF10 in OF culture differentiation medium. After incubation for various times (24, 48, 72 h)
with IL-1β (10 ng/ml), TGF-β (5 ng/ml) or TNF-α (10 ng/ml), the culture supernatants were
collected and ELISA was used to determine FGF10 levels.
rhFGF10 and siRNA transfection against FGF10
Cells were treated with rhFGF10 (100 ng/ml) or transfected with siFGF10 (100 ng/mL, 24 h)
following the manufacturer’s instructions. Approximately 70% of confluent OFs from patients
with GO and non-GO were prepared in 6-well plates. Negative control siRNA or FGF10
siRNA was transfected with a commercial reagent (TransIT-siQUEST1 Reagent; Mirus Bio,
Madison, WI, USA). After pretreatment of FGF10 or transfection with siFGF10, cells were
incubated with or without 10 ng/mL of IL-1β, TNF-α, or 5 ng/mL of TGF-β for 16 h.
Immunofluorescence (IF) staining
For IF staining, sections of paraffin-embedded orbital tissue were deparaffinized and rehy-
drated. After blocking with 3% BSA, the sections were incubated with anti-FGF10 antibody
(Santa Cruz Biotechnology) and Alexa Fluor Fluor-488 anti-mouse IgG (Molecular Probes™,
Thermo Fisher Scientific). For nuclear counterstaining, Fluoroshield™ with 4’,6-diamidino-
2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) was used. Fluorescence images were
captured with a microscope (IX73; Olympus Optical Co., Ltd., Tokyo, Japan) with a charge-
coupled device camera (DP71; Olympus Optical Co., Ltd.).
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Statistics
All experiments were performed at least three times with samples from each individual, and
sample assays were performed in duplicates. All results are expressed as means ± standard
deviation. Independent t-tests and one-way analysis of variance (ANOVA) with post-hoc anal-
ysis were used in this study. A statistical program (SPSS for Windows, version 26; SPSS, Chi-
cago, IL) was used, and values of P < 0.05 were considered significant.
Results
GO tissues and OFs show decreased expression of FGF10
We compared mRNA level of FGF10 and FGFR2b in GO (n = 10) and non-GO (n = 10)
orbital tissues explants using RT-PCR. mRNA transcript levels of FGF10 were greater in non-
GO tissue than in GO tissue (p = 0.01, independent t-test) as shown in Fig 1A. RNA transcript
levels of FGFR2b were also greater in non-GO tissue than in the GO tissue (p = 0.005, indepen-
dent t-test) (Fig 1A).
Microscopy images showing FGF10 (green) and live-cell nuclei (DAPI; blue) expression in
GO and non-GO orbital tissue confirmed immunostaining of FGF10 in control orbital adipose
tissue, which was, on the other hand, very weak in GO tissue (Fig 1B).
FGF10 proteins in primary cultured OFs were more expressed in non-GO OFs (n = 5) than
in GO OFs (n = 5) in western blot analyses (Fig 1C). Densitometry results showed a statistically
significant lower expressions of FGF10 in GO OFs than in non-GO OFs (p = 0.015, indepen-
dent t-test).
To identify the unique phenotype of GO OFs, fibronectin, COL1A, and α-SMA gene expres-
sion was compared between GO OFs (n = 3) and non-GO OFs (n = 3) using RT-PCR. The
mRNA transcript levels of fibronectin, COL1A, and α-SMA expression were significantly
higher in GO OFs than in non-GO OFs (Fig 1D).
Effects of TGF-β1 and rhFGF10 on fibronectin, collagen Iα, and α-SMA
protein expression in GO OFs
Since TGF-β is known to be important for the induction of tissue remodeling and fibrosis, we
investigated whether TGF-β could induce fibrotic processes in GO and non-GO OFs. By west-
ern blot analysis, we confirmed that fibrosis-related proteins, including fibronectin, collagen
Iα, and α-SMA, significantly increased in GO and non-GO OFs after stimulation with TGF-β
in a time-dependent manner (Fig 2).
To clarify the role of FGF10 in the fibrotic response, we treated GO and non-GO OFs with
rhFGF-10 for different times. Treatment of GO and non-GO OFs with 100 ng/mL rhFGF10
for 24 h or 48 h significantly repressed fibronectin, COL3A, and COL1A protein expression
(Fig 3).
Fibrosis and inflammation-induced the upregulation of FGF10 expression
in GO and non-GO OFs
After treatment with 10 ng/mL of IL-1β, TNF-α, and 5 ng/mL of TGF-β on OFs, the protein
levels were increased under inflammatory and fibrotic conditions (Fig 5). In addition, after
treatment with IL-1β, TNF-α, and TGF-β for 72 h, we also found that the expression of FGF10
protein increased gradually in GO and non-GO OFs by western blot analysis in a time-depen-
dent manner (Fig 4A).
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Fig 1. Expression of fibroblast growth factor 10 (FGF10) in Graves0 orbitopathy (GO) and in non-GO tissues and cells. (A) Expression
of fibroblast growth factor 10 (FGF10) and FGF receptor 2b (FGFR2b) mRNA in GO and non-GO orbital tissues. (B) Microscopy images
showing the expression of FGF10 (green) and live-cell nuclei (4’,6-diamidino-2-phenylindole dihydrochloride; blue) in GO and non-GO
orbital tissues. (C) Expression of FGF10 protein in GO and non-GO orbital fibroblasts (OFs). Bar graphs show the relative density of FGF10
normalized to the level of β-actin and are represented as means ± standard deviation. (D) Gene expression of fibronectin, collagen Iα, and
α- smooth muscle actin in GO and non-GO OFs. Experiments were performed at least three times using different strains. �p< 0.05,
��p< 0.01.
https://doi.org/10.1371/journal.pone.0255344.g001
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Since FGF10 is a secreted molecule, we also determined secreted FGF10 expression levels in
GO OFs under inflammatory and fibrotic conditions. After treatment with IL-1β, TNF-α, or
TGF-β (24–72 h), FGF10 protein expression was significantly higher in GO OFs (Fig 4B).
FGF10 overexpression or blockage altered TGF-β1 induced fibronectin,
COLIA, α-SMA protein expression
To address the role of FGF10, we treated GO OFs with rhFGF10 or transfected with siFGF10
to change the expression levels of FGF10 in GO OFs. After treatment with rhFGF10 (100 ng/
mL, 1 h) in GO OFs, TGF-β1 (5 ng/mL, 24 h) induced fibronectin, COL1A, and α-SMA pro-
tein expression substantially decreased (Fig 5). In contrast, knockdown of FGF10 via siFGF10
transfection (100 ng/mL, 24 h) induced an exaggerated increase in TGF-β-induced fibronectin,
COL1A, α-SMA, and MMP-2 expression (Fig 5).
Knockdown of FGF10 induced overexpression of IL-6, IL-8, and COX-2
proteins
We investigated whether FGF10 could contribute to the inflammatory response in GO OFs.
IL-1β (10 ng/mL, 16 h) induced IL-6, IL-8, and COX-2 protein expression further increased in
siFGF10 (100 ng/mL, 24 h) transfected OFs (Fig 6A). However, rhFGF10 (100 ng/mL) did not
Fig 2. Effect of transforming growth factor (TGF)-β1 on fibrosis-related protein production in the Graves0 orbitopathy (GO) and non-GO orbital
fibroblasts (OFs). After treatment of the OFs with 5 ng/mL TGF-β1 for 0, 1, 3, 6, 24, 48, and 72 h, the protein expression levels of fibronectin, collagen Iα, α-
smooth muscle actin increased in a time-dependent manner. Bar graphs show the relative density of each protein normalized to the level of β-actin and are
represented as mean ± standard deviation. Experiments were performed using at least cells using different strains. �p< 0.05.
https://doi.org/10.1371/journal.pone.0255344.g002
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Fig 3. Inhibitory effect of FGF10 on Graves0 orbitopathy (GO) and non-GO orbital fibroblasts. After treatment with 100
ng/mL of rhFGF10 for 0, 6, 24, and 48 h, fibronectin, collagen IIIa (COL3A) and collagen Iα (COL1A) protein expression was
significantly decreased at 24 h or 48 h. Bar graphs show the relative density of each protein normalized to the level of β-actin
and are represented as means ± standard deviation. Experiments were performed using at least three cells from different
strains. �p< 0.05.
https://doi.org/10.1371/journal.pone.0255344.g003
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suppress IL-1β induced IL-6, IL-8, COX-2, and ICAM-1 protein production, probably because
IL-1β was a too powerful inflammatory stimulant for FGF10 to compensate (Fig 6A).
In addition, we also treated GO OFs with TNF-α (10 ng/mL, 16 h) as another inflammatory
stimulant (Fig 6B). Similar to IL-1β stimulated data, TNF-α upregulated the production of IL-
6, IL-8, and COX-2 protein, which was further increased by blocking FGF10. Interestingly, the
expression levels of IL-6 and COX-2 protein were attenuated by the treatment of FGF10.
Fig 4. Effect of transforming growth factor (TGF)-β1, interleukin (IL)-1β, and tumor necrosis factor (TNF)-α on fibroblast
growth factor 10 (FGF10) expression in Graves0 orbitopathy (GO) and non-GO orbital fibroblasts (OFs). (A) Representative
western blot images showing that TGF-β1, IL-1β, and TNF-α increased expression of FGF10 at various time points (0–72 h) in both
GO and non-GO OFs. Bar graphs show the relative density of each protein normalized to the level of β-actin and are represented as
means ± standard deviation. (B) Expression levels in GO OFs of secreted FGF10 protein in response to TGF-β1, IL-1β, and TNF-α,
using ELISA. Experiments were performed at least three times using different strains. �p< 0.05.
https://doi.org/10.1371/journal.pone.0255344.g004
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FGF10 upregulated phosphorylation of ERK in non-GO and GO OFs
To identify signaling pathways affected by the regulation of FGF10, phosphorylation of ERK
was assayed. rhFGF10 (100 ng/ml) treatment increased the levels of phosphorylated ERK sig-
naling molecules in GO and non-GO OFs (Fig 7).
Discussion
In this study, we investigated the roles of FGF10 in the pathogenesis of GO, especially in fibro-
sis and inflammation. First, we compared expression levels of FGF10 and FGFR2b between
Fig 5. Effect of upregulation of fibroblast growth factor 10 (FGF10) using recombinant human (rh) FGF10 or blockage of FGF10 by small interfering (si)
FGF10 transfection on transforming growth factor (TGF)-β1 induced fibrosis-related protein expression. The rhFGF10 suppressed the TGF-β1 induced
fibronectin, collagen Iα (COL1A), and α-smooth muscle actin (α-SMA) expression in Graves0 orbitopathy (GO) orbital fibroblasts (OFs). Knockdown of
FGF10 induced the increase of TGF-β1 induced fibronectin, COL1A, and α-SMA expression in GO OFs. Bar graphs show the relative density of each protein
normalized to the level of β-actin and are represented as mean ± standard deviation. Experiments were performed in at least three cells cultured from different
strains. �p< 0.05, ��p< 0.01.
https://doi.org/10.1371/journal.pone.0255344.g005
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Fig 6. Effect of upregulation of fibroblast growth factor 10 (FGF10) using recombinant human (rh) FGF10 or
blockage of FGF10 by small interfering (si) FGF10 transfection on interleukin (IL)-1β or tumor necrosis factor
(TNF)-α induced proiflammatory protein expression. (A) FGF10 did not suppress IL-1β induced IL-6, IL-8,
cyclooxygenase (COX)-2, and intercellular adhesion molecule-1 (ICAM-1) in Graves0 orbitopathy (GO) orbital
fibroblasts (OFs). However, knockdown of FGF10 induced the increase of IL-1β induced IL-6, IL-8 and COX-2
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GO and non-GO tissues and cells; FGF10 was significantly downregulated in GO compared to
non-GO specimens, whereas the mRNA transcript levels of fibronectin, COL1A, and α-SMA
expression were higher in GO OFs than non-GO OFs. In addition, fibrotic and proinflamma-
tory stimuli induced the upregulation of FGF10 expression in a time-dependent manner in
both GO and non-GO OFs. TGF-β1 induced fibronectin, COL1A, and α-SMA protein expres-
sion in GO OFs was attenuated by rhFGF10 treatment; however, it was further increased by
knockdown of FGF10 via siFGF10 transfection. Knockdown of FGF10 via siFGF10 increased
the expression levels of IL-1β- and TNF-induced IL-6, IL-8, and COX-2 protein expression.
Moreover, overexpression of FGF10 via rhFGF10 led to a decrease in the expression levels of
TNF-α-induced IL-6 and COX-2. Based on these results, FGF10 might have a protective role
not only in fibrosis and but also in inflammation as well. Considering the anti-inflammatory
expression in GO OFs. (B) FGF10 treatment attenuated expression of TNF-a induced IL-6 and COX-2 protein.
However, knockdown of FGF10 induced the increase of TNF-α induced IL-6, IL-8, COX-2, and ICAM-1 expression.
Bar graphs show the relative density of each protein normalized to the level of β-actin and are represented as
mean ± standard deviation. Experiments were performed in at least three cells cultured from different strains.
��p< 0.01.
https://doi.org/10.1371/journal.pone.0255344.g006
Fig 7. Role of fibroblast growth factor 10 (FGF10) in the phosphorylation of signaling molecule, extracellular signal-regulated kinase (ERK). The increase
of phosphorylation of ERK was noted in rhFGF10 treated orbital fibroblasts from Graves0 orbitopathy (GO) and non-GO patients. The phosphorylation of ERK
gradually increased and decreased after peaking at 30 minutes of treatment. Bar graphs show the relative density of each protein normalized to the level of β-
actin and are represented as mean ± standard deviation. Experiments were performed in at least three cells cultured from different strains. �p< 0.05.
https://doi.org/10.1371/journal.pone.0255344.g007
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and anti-fibrotic role of FGF10, as shown in our data, the lack of FGF 10 expression in GO
orbit may have induced or aggravated the GO phenotype.
FGF10 is a paracrine signaling growth factor of 215 amino acids and plays an important
role during tissue homeostasis in adults [13]. Following injury, FGF10 robustly increases in
the wound microenvironment and has further demonstrated some ability to promote wound
healing in vitro and in vivo. Initial in vitro wound healing studies demonstrated that FGF10
promotes proliferation and differentiation of human keratinocytes, suggesting its likely role in
epidermal growth and differentiation [21]. After analyzing the data regarding the role of
FGF10 in fibrosis, it can be inferred that its role in the fibrotic process is complex because indi-
vidual FGF family members may exert pro-and anti-fibrotic effects, depending on the
responding cell type as well as the context of other signaling molecules [22]. Moreover, FGF
subfamilies usually share FGFR. Among other FGFs that can share the receptor with the oth-
ers, some members of FGF can act as ‘pro-fibrotic’ through their mitogenic activity on fibro-
blasts, while others have ‘anti-fibrotic’ effects by promoting epithelial cell regeneration [22].
Thus, the role of FGF10 in fibrosis is complex. For example, FGF10 levels were reduced in the
lungs of aged mice before and after the injury and in idiopathic pulmonary fibrosis patients
with the progressive disease compared with stable disease [23]. One study showed that FGF10
could prevent or reduce lung-specific inflammation/ fibrosis due to traumatic or infectious
lung injury [24]. We, for the first time, demonstrated that FGF10 blocked TGF-β induced
fibrosis-related protein expression in primary cultured OFs and also found diminished tissue
level of FGF10 in GO tissues than in non-GO tissues. Recently, Sun et al. [15] reported that
reduced expression of FGF10/FGFR2 was found in fibrotic retinal tissues and NRK52E cells
with DBP exposure, and these findings are consistent with our results. However, there are con-
tradictory results regarding FGF10 and fibrosis. In another study on FGFR antagonists, inhibi-
tion of endogenous FGFR2b ligands (FGF7 and FGF10) does not alter bleomycin-induced
pulmonary fibrosis, suggesting that these ligands are not essential for fibrosis [25, 26].
Studies regarding the role of FGF10 in inflammation have shown that FGF10 is overex-
pressed in psoriatic skin, which is an autoimmune disease [27, 28]. FGF10 is known to protect
neurons against oxygen-glucose deprivation injury in vitro, and FGF10 treatment depressed
the triggered inflammatory factors of the TNF-α, IL-6, and nuclear factor-κB signaling path-
ways in a mouse middle cerebral artery occlusion model [29]. FGF10 treatment inhibited the
release of pro-inflammatory cytokines after spinal cord injury in vivo [30]. Data regarding the
effects of FGF10 on inflammation have also been contradictory. In one study, FGF10 pro-
moted epithelial cell proliferation via stimulation of COX-2 expression and upregulation of
prostaglandin E2 production [31]. In another, anti-FGF10 monoclonal antibody inhibited pro-
liferation of human keratinocytes and reduced inflammation in propranolol-induced psoria-
sis-like lesions. Therefore, our findings may provide proof of principle that blockage of FGF10
can inhibit psoriasis-related inflammation [32].
In this study, although basal levels of FGF10 differed between GO and non-GO orbital tis-
sues and primary cells, the inhibitory effect of FGF10 on fibrosis did not differ between GO
and non-GO cells. According to previous studies [20, 33–35], GO and non-GO cells under pri-
mary culture conditions often show similar patterns of response to stimulation and inhibition
of specific targets that may not reflect actual clinical events. Nonetheless, it is notable that our
study found a significant difference in FGF10 expression levels between GO and non-GO tis-
sues and OFs.
In conclusion, the precise mechanism by which FGF10 is involved in GO pathogenesis is
not clear; however, the fibrotic and inflammatory processes were reduced by FGF10 treatment
in the present study. Using a rabbit model of corneal CO2 laser injury, topical FGF-10 was
shown to accelerate corneal epithelial wound healing and reduce inflammation, stromal
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edema, and fibrosis [32]. Although therapeutic approaches using exogenous FGFs, antibodies,
or small molecules are still challenging, and many avenues of the investigation remain open,
this study provides the concept that therapeutic strategies aimed directly at FGF10 could be
beneficial in the treatment of GO.
Supporting information
S1 Fig. Full length gels representative of Western blot analysis for Figs 1 and 2.
(TIF)
S2 Fig. Full length gels representative of Western blot analysis for Fig 3.
(TIF)
S3 Fig. Full length gels representative of Western blot analysis for Figs 4 and 5.
(TIF)
S4 Fig. Full length gels representative of Western blot analysis for Figs 6 and 7.
(TIF)
Author Contributions
Conceptualization: Jin Sook Yoon.
Methodology: Soo Hyun Choi.
Supervision: Jin Sook Yoon.
Writing – original draft: Sun Young Jang.
Writing – review & editing: Sun Young Jang, Don Kikkawa, Eun Jig Lee, Jin Sook Yoon.
References
1. Wiersinga WM. (2017) Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy.
Lancet Diabetes Endocrinol. 5(2):134–142. https://doi.org/10.1016/S2213-8587(16)30046-8 PMID:
27346786
2. Virakul S, Heutz JW, Dalm VA, Peeters RP, Paridaens D, van den Bosch WA, et al. (2016) Basic FGF
and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Mol Cell
Endocrinol. 433:94–104. https://doi.org/10.1016/j.mce.2016.05.023 PMID: 27267669
3. Bahn RS. (2015) Current Insights into the Pathogenesis of Graves’ Ophthalmopathy. Horm Metab Res.
47(10):773–778. https://doi.org/10.1055/s-0035-1555762 PMID: 26361262
4. Yoon JS, Chae MK, Jang SY, Lee SY, Lee EJ. (2012) Antifibrotic effects of quercetin in primary orbital
fibroblasts and orbital fat tissue cultures of Graves’ orbitopathy. Invest Ophthalmol Vis Sci. 53(9):5921–
5929. https://doi.org/10.1167/iovs.12-9646 PMID: 22871832
5. Jang SY, Park SJ, Chae MK, Lee JH, Lee EJ, Yoon JS. (2018) Role of microRNA-146a in regulation of
fibrosis in orbital fibroblasts from patients with Graves’ orbitopathy. Br J Ophthalmol. 102(3):407–414.
https://doi.org/10.1136/bjophthalmol-2017-310723 PMID: 29101123
6. Bartley GB. (2011) Rundle and his curve. Arch Ophthalmol. 129(3):356–358. https://doi.org/10.1001/
archophthalmol.2011.29 PMID: 21402995
7. Gospodarowicz D. (1974) Localisation of a fibroblast growth factor and its effect alone and with hydro-
cortisone on 3T3 cell growth. Nature. 249(453):123–127. https://doi.org/10.1038/249123a0 PMID:
4364816
8. Beenken A, Mohammadi M. (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev
Drug Discov. 8(3):235–253. https://doi.org/10.1038/nrd2792 PMID: 19247306
9. Ornitz DM, Itoh N. (2015) The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev
Biol. 4(3):215–266. https://doi.org/10.1002/wdev.176 PMID: 25772309
PLOS ONE Role of fibroblast growth factor 10 in Graves’ orbitopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0255344 August 12, 2021 14 / 16
10. Ye X, Liu J, Wang Y, Bin L, Wang J. (2014) Increased serum VEGF and b-FGF in Graves’ ophthalmo-
pathy. Graefes Arch Clin Exp Ophthalmol. 252(10):1639–1644. https://doi.org/10.1007/s00417-014-
2662-y PMID: 24867311
11. Pawlowski P, Reszec J, Eckstein A, Johnson K, Grzybowski A, Chyczewski L, et al. (2014) Markers of
inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical
implications. Mediators Inflamm. 2014:412158. https://doi.org/10.1155/2014/412158 PMID: 25309050
12. Nunes QM, Li Y, Sun C, Kinnunen TK, Fernig DG. (2016) Fibroblast growth factors as tissue repair and
regeneration therapeutics. PeerJ. 4:e1535. https://doi.org/10.7717/peerj.1535 PMID: 26793421
13. Itoh N. (2016) FGF10: A multifunctional mesenchymal-epithelial signaling growth factor in development,
health, and disease. Cytokine Growth Factor Rev. 28:63–69. https://doi.org/10.1016/j.cytogfr.2015.10.
001 PMID: 26559461
14. Gupte VV, Ramasamy SK, Reddy R, Lee J, Weinreb PH, Violette SM, et al. (2009) Overexpression of
fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced
pulmonary fibrosis in mice. Am J Respir Crit Care Med. 180(5):424–436. https://doi.org/10.1164/rccm.
200811-1794OC PMID: 19498056
15. Sun WL, Zhu YP, Ni XS, Jing DD, Yao YT, Ding W, et al. (2018) Potential involvement of Fgf10/Fgfr2
and androgen receptor (AR) in renal fibrosis in adult male rat offspring subjected to prenatal exposure
to di-n-butyl phthalate (DBP). Toxicol Lett. 282:37–42. https://doi.org/10.1016/j.toxlet.2017.09.009
PMID: 28919491
16. Lu W, Luo Y, Kan M, McKeehan WL. (1999) Fibroblast growth factor-10. A second candidate stromal to
epithelial cell andromedin in prostate. J Biol Chem. 274(18):12827–12834. https://doi.org/10.1074/jbc.
274.18.12827 PMID: 10212269
17. Bagai S, Rubio E, Cheng JF, Sweet R, Thomas R, Fuchs E, et al. (2002) Fibroblast growth factor-10 is
a mitogen for urothelial cells. J Biol Chem. 277(26):23828–23837. https://doi.org/10.1074/jbc.
M201658200 PMID: 11923311
18. Watson J, Francavilla C. (2018) Regulation of FGF10 Signaling in Development and Disease. Front
Genet. 9:500. https://doi.org/10.3389/fgene.2018.00500 PMID: 30405705
19. Jang SY, Chae MK, Lee JH, Lee EJ, Yoon JS. (2019) MicroRNA-27 inhibits adipogenic differentiation in
orbital fibroblasts from patients with Graves’ orbitopathy. PLoS One. 14(8):e0221077. https://doi.org/
10.1371/journal.pone.0221077 PMID: 31415657
20. Ko J, Chae MK, Lee JH, Lee EJ, Yoon JS. (2017) Sphingosine-1-Phosphate Mediates Fibrosis in
Orbital Fibroblasts in Graves’ Orbitopathy. Invest Ophthalmol Vis Sci. 58(5):2544–2553. https://doi.org/
10.1167/iovs.16-20684 PMID: 28492873
21. Marchese C, Felici A, Visco V, Lucania G, Igarashi M, Picardo M, et al. (2001) Fibroblast growth factor
10 induces proliferation and differentiation of human primary cultured keratinocytes. J Invest Dermatol.
116(4):623–628. https://doi.org/10.1046/j.0022-202x.2001.01280.x PMID: 11286634
22. Kim KK, Sisson TH, Horowitz JC. (2017) Fibroblast growth factors and pulmonary fibrosis: it’s more
complex than it sounds. J Pathol. 241(1):6–9. https://doi.org/10.1002/path.4825 PMID: 27757968
23. Chanda D, Kurundkar A, Rangarajan S, Locy M, Bernard K, Sharma NS, et al. (2016) Developmental
Reprogramming in Mesenchymal Stromal Cells of Human Subjects with Idiopathic Pulmonary Fibrosis.
Sci Rep. 6:37445. https://doi.org/10.1038/srep37445 PMID: 27869174
24. Tong L, Zhou J, Rong L, Seeley EJ, Pan J, Zhu X, et al. (2016) Fibroblast Growth Factor-10 (FGF-10)
Mobilizes Lung-resident Mesenchymal Stem Cells and Protects Against Acute Lung Injury. Sci Rep.
6:21642. https://doi.org/10.1038/srep21642 PMID: 26869337
25. MacKenzie B, Henneke I, Hezel S, Al Alam D, El Agha E, Chao CM, et al. (2015) Attenuating endoge-
nous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repair.
Am J Physiol Lung Cell Mol Physiol. 308(10):L1014–1024. https://doi.org/10.1152/ajplung.00291.2014
PMID: 25820524
26. Guzy RD, Li L, Smith C, Dorry SJ, Koo HY, Chen L, et al. (2017) Pulmonary fibrosis requires cell-auton-
omous mesenchymal fibroblast growth factor (FGF) signaling. J Biol Chem. 292(25):10364–10378.
https://doi.org/10.1074/jbc.M117.791764 PMID: 28487375
27. Finch PW, Murphy F, Cardinale I, Krueger JG. (1997) Altered expression of keratinocyte growth factor
and its receptor in psoriasis. Am J Pathol. 151(6):1619–1628. PMID: 9403712
28. Kovacs D, Falchi M, Cardinali G, Raffa S, Carducci M, Cota C, et al. (2005) Immunohistochemical anal-
ysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis. Exp Dermatol.
14(2):130–137. https://doi.org/10.1111/j.0906-6705.2005.00261.x PMID: 15679583
29. Li YH, Fu HL, Tian ML, Wang YQ, Chen W, Cai LL, et al. (2016) Neuron-derived FGF10 ameliorates
cerebral ischemia injury via inhibiting NF-κB-dependent neuroinflammation and activating PI3K/Akt sur-
vival signaling pathway in mice. Sci Rep. 6:19869. https://doi.org/10.1038/srep19869 PMID: 26813160
PLOS ONE Role of fibroblast growth factor 10 in Graves’ orbitopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0255344 August 12, 2021 15 / 16
30. Chen J, Wang Z, Zheng Z, Chen Y, Khor S, Shi K, et al. (2017) Neuron and microglia/macrophage-
derived FGF10 activate neuronal FGFR2/PI3K/Akt signaling and inhibit microglia/macrophages TLR4/
NF-κB-dependent neuroinflammation to improve functional recovery after spinal cord injury. Cell Death
Dis. 8(10):e3090. https://doi.org/10.1038/cddis.2017.490 PMID: 28981091
31. Han DS, Li F, Holt L, Connolly K, Hubert M, Miceli R, et al. (2000) Keratinocyte growth factor-2 (FGF-
10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol Gastrointest Liver
Physiol. 279(5):G1011–1022. https://doi.org/10.1152/ajpgi.2000.279.5.G1011 PMID: 11052999
32. Yao N, Xia JX, Liu XM, Wang N, Mmi XG, Wang YF, et al. (2014) Topical application of a new monoclo-
nal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like
lesions in guinea pigs. Eur Rev Med Pharmacol Sci. 18(7):1085–1091. PMID: 24763891
33. Lee GE, Kim J, Lee JS, Ko J, Lee EJ, Yoon JS. (2020) Role of Proprotein Convertase Subtilisin/Kexin
Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts. Front Endocrinol (Lausanne).
11:607144. https://doi.org/10.3389/fendo.2020.607144 PMID: 33488522
34. Byeon HJ, Kim JY, Ko J, Lee EJ, Don K, Yoon JS. (2020) Protein tyrosine phosphatase 1B as a thera-
peutic target for Graves’ orbitopathy in an in vitro model. PLoS One. 15(8):e0237015. https://doi.org/
10.1371/journal.pone.0237015 PMID: 32760098
35. Lee JS, Chae MK, Kikkawa DO, Lee EJ, Yoon JS. (2020) Glycogen Synthase Kinase-3βMediates
Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves’
Orbitopathy. Invest Ophthalmol Vis Sci. 61(8):51. https://doi.org/10.1167/iovs.61.8.51 PMID:
32735324
PLOS ONE Role of fibroblast growth factor 10 in Graves’ orbitopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0255344 August 12, 2021 16 / 16
